| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | U | V | W | X | Y | Z | AA | AB | AC | AD | AE | AF | AG | AH | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | (How to Use This Table) | is it aging? | operating status | short summary (intended to be objective, usually from company material, edited for brevity) | clinical stage (and pipeline) | therapy or diagnostic | category(-ies) | hallmark(s) | SENS area(s) | diseases / indications | clinical trials | modalities | regulatory category | team/principals (esp. scientific) | (scientific) advisors | contact info | geo(s) | public? | ticker (Yahoo) | market cap (M) | employees (publics, Y!) | employees (LinkedIn) | year founded | private funding stage | notable investors | total raised ($M) | other relations | lead product(s) | publications | patents | date updated | add date if >Oct'19 | other notes | |
2 | 5 Alarm Bio | yes | operating | drugs to boost natural cell defenses against damaging chemicals that arise naturally & accumulate w/ age | pre-clinical | therapy | small molecules | pharmaceutical | William Bains | Aubrey de Grey, Joao Pedro de Magalhaes | william@fivealarmbio.com | Cambridge, UK | no | 2016 | FAB001 | 8/28/19 | ||||||||||||||||||
3 | 712 North Inc | yes | operating | mitochondria modulators for age-related diseases | pre-clinical | therapy | mitochondria | mitochondria | MitoSENS | AD, cancer, glaucoma, CVD, unspecificed orphan pediatric disease | pharmaceutical | Marcel Alavi | San Francisco | no | 2 | 2016 | QB3 | 9/4/19 | ||||||||||||||||
4 | Aeovian (formerly Aeonian) | yes | operating | selective mTORC1 inhibition | pre-clinical | therapy | metabolic / mTOR | nutri-sense | small molecule | pharmaceutical | Stelios Tzannis, Curtis Scribner | Ian Massey, David Lowe, Dudley Lamming, Mustafa Sahin, Jacqueline French | form | San Francisco | no | 3 | 2012 | raised A | Apollo, venBio, Sofinnova | 37 | AE116 | paper | 10/8/19 | |||||||||||
5 | Age Labs | yes | operating | ML on methylation data mortality clock from longitudinal (45yrs) data, for improved clinical trials | pre-commercial | diagnostic | biomarkers / methylome clock | epigenetic | blood test | unregulated test | Espen Riskedal, Arne Soraas, Karl Kalleberg | Oslo, Norway | no | 2 | 2017 | Norway | 9/4/19 | |||||||||||||||||
6 | AgeCurve Limited | yes | operating | DTC proteomics from saliva covering 4 of 9 hallmarks, using mass spec & ML | commercial | diagnostic | biomarker / proteome | saliva sample | unregulated test | Attila Csordas | Cambridge, UK | no | 2 | 2015 | raised seed | 9/21/19 | Commercial launched in UK. Pilot status in US. | |||||||||||||||||
7 | AgeX Therapeutics | yes | operating | allogeneic stem cells w/ tech for stable engraftment & low immunogenicity; tissue regeneration drugs | pre-clinical | therapy | stem-cells, reprogramming | stem-cells, nutri-sense, epigenetic | RepleniSENS | IHD, T2D, CHF, scarless healing | cell therapy, small molucels | pharmaceutical | Mike West, Aubrey de Grey | San Francisco | yes | AGE | $54 | 12 | 9 | 2017 | Juvenescence, Jim Mellon, John Mauldin, Kizoo | Juvenescence | VASC1, BAT1, iTR1547, Renelon | 9/18/19 | ||||||||||
8 | Alector | only brain | operating | trigger immune system to cure dementias w/ leads based on GWAS | ph.2 trials | therapy, diagnostic | AD, FTD, neuroDs | 4 | biologics | pharmaceutical | Arnon Rosenthal, Robert Paul | Adam Boxer, Marco Colonna, Stephen Hauser, Michael Heneka, Lewis Lanier, Liqun Luo, Richard Scheller, Thomas Christian Südhof, Robert Vassar, Berislav Zlokovic | San Francisco | yes | ALEC | $1,067 | 101 | 104 | 2013 | Orbimed, Polaris, GV, Merck, MBC, AbbVie, Amgen | AbbVie | AL001, AL101, AL002, AL003 | many papers | 9/18/19 | ||||||||||
9 | Alkahest | yes | operating | leads from blood proteins that go up or down with age, eg young blood fractions, eotaxin/CCR3 inhibition | ph.2 trials | therapy | factors | cell-comm | AD, PD, (wet) AMD | 7 | drugs, biologics, blood fractions | pharmaceutical | Karoly Nikolich, Steven Braithwaite | Tony Wyss-Coray, Jeffrey Cummings, Lennart Mucke, Thomas Rando, Eric Reiman, Lee Rubin, Elia Stupka, Saul Villeda | San Francisco | no | 71 | 2014 | post-seed | Grifols, MJFox Found | 50 | Grifols | AKST4290, AKST/GRF6019/6021, AKST1210 | papers | 9/21/19 | |||||||||
10 | Altoida | only brain | operating | augmented reality & AI mobile app 10min cognitive test, FDA cleared & covered by Medicare | commercial | diagnostic | biomarker | AD, other MCI | 1 | mobile app | regulated diagnostic (SaMD) | Richard Fischer, Ioannis Tarnanas | Walter Greenleaf, Jon VanLeeuwen, Phil Polakoff | contact@altoida.com | Houston | no | 13 | 2016 | raised A | M Ventures, Fyrfly | 8.3 | NMI (Neuro Motor Index) | peer reviewed paper | 7/22/19 | ||||||||||
11 | Ambrosia | yes | defunct (also see notes) | young blood transfusions via self-paid clinical trial | clinical trial, phase n/a | therapy | factors | cell-comm | 1 | blood transfusion | Jesse Karmazin? | no | 2016 | 8/4/19 | ambrosiaplasma.com & linkedin.com/in/jessekarmazin not up despite claims restarting (bizjournals.com/sanjose/news/2019/06/17/ambrosia-health-young-blood-startup-fda.html). More details: https://www.bloomberg.com/news/articles/2019-02-25/the-bloody-tale-of-ambrosia-the-startup-that-wants-to-slow-aging | |||||||||||||||||||
12 | Amprion | only brain | operating | amplification of misfolded proteins for sensitive detection in CSF & blood, for αS (1st), Aβ, tau | pre-clinical, breakthrough designation | diagnostic | proteostasis | proteostasis | AmyloSENS | PD, AD | CSF | regulated test or device? | Russ Lebovitz, Claudio Soto, Luis Concha | Info@AmprionMe.com | San Diego, San Francisco | no | 8 | 2007 | 9/30/2019 | Breakthrough device designation from FDA in May 2019 for alpha-Synuclein. Not to be confused with the Germany electrical grid company of the same name. | ||||||||||||||
13 | Animal Biosciences | yes | operating | healthy longevity for pets (primarily dogs, cats, horses) | pre-commercial | therapy | small molecules, supplemens | veterinary | Doug Korn, Nick Sinclair | form | Boston | no | 6 | Life Bio | Life Bio | 10/8/19 | ||||||||||||||||||
14 | Athersys Inc | yes | operating | allogeneic stem cells for neuro, inflammatory, immune, & CV diseases | ph.3 trials | therapy | stem-cells | stem-cells | RepleniSENS | neuroDs, CVD, others | 9 | cell therapy | pharmaceutical | Gil Van Bokkelen, John Harrington, William (BJ) Lehmann, Robert (Willie) Mays, Anthony Ting | info@athersys.com | Cleveland, OH | yes | ATHX | $222 | 75 | 89 | 1995 | MultiStem | 7/11/19 | ||||||||||
15 | Atropos Therapeutics | yes | operating | drug platform for modulators of entering senescence, for aging (suppress) & cancer (stimulate) | pre-clinical | therapy | senescence | senescence | cancer, progeroidDs, undecided agingDs | small molecules? | pharmaceutical | Tommy Nguyen, Andrew Koff | Jan Vijg, John Sedivy, William Tap, John Petrini, Oliver Stauch | info@atroposthera.com | San Francisco | no | 3 | 2018 | QB3 | some relevant papers | 8/2/19 | |||||||||||||
16 | BioAge Labs | yes | operating | drug discovery platform based on multi-omics on human biobanks w/ 20+yr health records + AI | pre-clinical | therapy | biomarker, ? | drugs | pharmaceutical | Kristen Fortney, Eric Morgen, Klaus Klumpp, Robert Hughes, Justin Rebo, | George Hartman, Elad Gil, Joe Betts-Lacroix, Peter Dilaura | info@bioagelabs.com | San Francisco | no | 21 | 2015 | closed B | Felicis, Andreessen Horowitz, Khosla, AME Cloud, Pear, Redpoint, Caffeinated Captial, Elad Gil | 33.9 | 7/24/19 | ||||||||||||||
17 | Biophytis | yes | operating | drug discovery platform for aging based on plant secondary metabolites | ph.2 trials | therapy | sarcopenia, AMD, MD | 2 | small molecules | pharmaceutical | Stanislas Veillet, Rene Lafont, Samuel Agus, Pierre Dilda, Waly Dioh | Jean Mariani, Roger Fielding, Thomas Voit, Jose-Alain Sahel, Ivana Kim | form | Paris | yes | ALBPS.PA | $4 | 30 | 26 | 2006 | Sarconeos (BIO101), Macuneos (BIO201) | several papers & posters | 7/11/19 | |||||||||||
18 | Bioquark | yes | operating | biologics for regeneration, repair, degenerative diseases w/ leads from regenerative animals | ph.1 trials | therapy | cancer, kidneyDs, neuroDs, brain death | 1 | biologics, cell therapy | pharmaceutical | Ira Pastor, Sergei Paylian | Calixto Machado, Melisa Cooper, Alejandro Mesples, Nikolai Skiba | form | Philadelphia, Tampa | no | 10 | 2007 | BQ-A | two (see bottom) | 7/28/19 | ||||||||||||||
19 | BioViva | yes | operating | platform for health tests & treatments (via partners) w/ focus on gene & cell therapies, also counseling | commercial | Elizabeth Parrish, Jason Williams, Anca Selariu, Mitch Fernandez, David Kekich | George Church, Bill Zheng, Anders Sandberg, John Schloendorn, Ali Fallah, Aubrey de Grey, Matthew Scholz, Hernando Ramirez Llinas | form | Seattle | no | 3 | 2015 | Integrated Health Systems | 8/13/19 | CEO Parrish underwent out-of-USA gene therapy to extend her telomeres w/ hTERT and for myostatin inhibition then claimed positive results, back when company focus was more directly telomere extension therapy. See also https://en.wikipedia.org/wiki/BioViva | |||||||||||||||||||
20 | BYOMass Therapeutics | yes | operating | control of metabolism for aging / age-related diseases | pre-clinical | therapy | metabolism | nutri-sense | pharmaceutical | Margaret Jackson | Massachusetts | no | 1 | 2017 | raised seed | Juvenescence | 6.5 | Juvenescence | 7/30/19 | |||||||||||||||
21 | Calico | yes | operating | broad mission to improve health and longevity using technology to advance biological science | therapy | pharmaceutical | Arthur Levinson, David Botstein, Cynthia Kenyon, Daniel Gottschling | press@calicolabs.com | San Francisco | no | 180 | 2013 | raise 2 rounsd from: | Google, Abbvie | 2500 | Google, AbbVie | several | 8/19/19 | Initially funded/created within Google/Alphabet. | |||||||||||||||
22 | CellAge | yes | operating? | develop new, more accurate senescent cell measurement based on synthetic promoters | research, pre-commercial | diagnostic | senescence | senescence | ApoptoSENS | unregulated test | Mantas Matjusaitis, Azuolas Ciukas | Alexandra Stolzing, Juan Carlos Acosta | INFO@CELLAGE.ORG | Glasgow, Scotland | no | 2 | 2016 | raised seed | Kizoo | Circularis | 8/2/19 | Website is .org. Seed raise was 2017 & involved crowdfunding. No mention of total raised. Still only 2 employees? Is this a for-profit company? | ||||||||||||
23 | Celularity | yes | operating | allogeneic cell therapies from postpartum human placentas, for cancer & functional regeneration | ph.2 trials | therapy | stem-cells, regeneration | stem-cells | RepleniSENS | cancer (solid & blood), others | cell therapy | pharmaceutical | Robert Hariri, Xiaokui Zhang, Nassir Habboubi | media@celularity.com | New York | no | 155 | 2016 | Celgene, Bill Maris, Tony Robbins, Human Longevity | 290 | CYNK-001 | thousands | 8/19/19 | Also run income generating programs to bank placental stem cells and to treat burns & wounds, with projected $40M revenue. | ||||||||||
24 | Centers for Age Control | yes | operating | sells AgeMeter multimodal test of biological age (successor to H-SCAN test) | commercial | diagnostic | biomarker | multimodal test | unregulated test | Elliot Small | info@agemeter.com | Las Vegas | no | 1 | 2005 | crowdfunded | AgeMeter | 8/22/19 | ||||||||||||||||
25 | Cerevance | only brain | operating | drug discovery platform by analyzing brain cell transcriptome diffs by age, cell type, region, & disease | ph.1 trials | therapy | PD, AD, neuroDs | 3 | small molecules, mAbs | pharmaceutical | Brad Margus, Mark Carlton, David Margolin, Lee Dawson, Roland Burli | Nathaniel Heintz, William Ray, Robert Malenka, James Summers, Jeremy Nathans, Rudolph Tanzi | info@cerevance.com | Boston | no | 31 | 2016 | raised A | Takeda Pharm, Dementia Discovery Fund, Lightstone | 26.5 | CVN424 | https://elifesciences.org/articles/37551 | 7/28/19 | |||||||||||
26 | ChromaDex Corporation | yes | operating | nutraceuticals for aging, esp. flagship product Niagen w/ nicotinamide riboside (NR), an NAD+ precursor | commercial, ph.3 trials | therapy | NAD+ | cancer, neuropathy, MCI, aging, obesity, heart failure, mitoDs, peripheral artery diseases, hypertension | 13 | nutraceuticals | nutraceutical | Rob Fried, Frank Jaksch Jr., Matthew Roberts | Roger Kornberg, John Walker, Rudolph Tanzi, Charles Brenner, Rob Beudeker, Bruce German | multiple emails & form | Los Angeles | yes | CDXC | $207 | 100 | 95 | 1999 | Niagen | many | 8/5/19 | 13 clinical trials mentioning Chromadex, but fewer sponsored by Chromadex and 23 trials using Niagen (some just not mentioning Chromadex by name). | |||||||||
27 | Chronomics | yes | operating | DTC saliva methylation clock, plus software to improve health | commercial | diagnostic | biomarkers / methylome clock | saliva sample | unregulated test | Tom Stubbs, Robin Thompson, Daniel Herranz | Janet Thornton, Paolo Vineis | info@chronomics.co.uk | London | no | 12 | 2017 | raised seed | SOSV, Anthemis, RebelBio | 1.3 | EpiHealth | 10/18/19 | |||||||||||||
28 | Cleara Biotech | yes | operating | senolytics, initially based on FOXO4-p53 interfering peptide | pre-clinical | therapy | senescence | senescence | ApoptoSENS | peptide or small molecules? | pharmaceutical | Peter De Keizer, Tobias Madl, Marco Demaria | Boudewijn Burgering | form | Netherlands | no | 5 | 2018 | raised seed | Apollo | several, esp. Cell 2017 | 7/11/19 | ||||||||||||
29 | CohBar Inc | yes | operating | find mtDNA peptides (eg that decrease w/ age) & optimized analogs to treat metabolic dysfunction | ph.1 trials | therapy | mitochondria | mitochondria | MitoSENS | NASH, obesity, T2D, cancer, other ageDs | 1 | peptides | pharmaceutical | Steven Engle, Kenneth Cundy, Nir Barzilai, ... | Amir Lerman, David Sinclair, Ronald Kahn, James Livingston, Frank Calzone | info@cohbar.com | San Francisco | yes | CWBR | $83 | 11 | 14 | 2007 | CB4211 | papers & posters | 10/16/19 | ||||||||
30 | Continuum Biosciences | yes | operating | drugs to improve mitochondria health & metabolism (eg to increase metabolism) | pre-clinical | therapy | mitochondria | mitochondria, nutri-sense | NASH, obesity, diabetes | drugs | pharmaceutical | Simon Tucker, Webster Santos, Kyle Hoehn | John Amatruda, David Sinclair | form | Blacksburg, VA | no | 2 | 2017 | raised seed | Life Bio | 0.5 | Life Bio | 10/17/19 | Not to be confused with Continuum Biosciences Consulting: https://www.continuumbiosciences.com/ | ||||||||||
31 | Covalent Bioscience | yes | operating | platform for catalytic antibodies (w/ advantages over mAbs) 1st for ATTR & Aβ, electrophilic vaccines | pre-clinical | therapy, preventative | proteostasis, targeted elimination | proteostasis | AmyloSENS | CVD, AD, HIV | pharmaceutical | Richard Massey, Sudhir Paul, Stephanie Planque | Robert Friedland, Joel Buxbaum, Miguel Escobar, Carl Hanson, Seth Pincus | form | Houston, New York | no | 3 | 2011 | several peer reviewed | 8/3/19 | ||||||||||||||
32 | Cytegen | yes | defunct? | exercise mimetic biologics to treat mitochondria dysfunction | pre-clinical | therapy | mitochondria, metabolism | mitochondria | AD, Parkinson's | biologics | pharmaceutical | George Ugras, Blake Hill | Milwaukee, WI | no | 2 | 2015 | raised unspecified | Breakout | 1 | 11/7/19 | Website found by Google summer/fall 2019 but website did not respond. | |||||||||||||
33 | Daphnia Labs | yes | operating | drug discovery platform via in-vivo phenotypic screens of daphnia water fleas w/ video & ML for anti-aging | pre-clinical | therapy | lifespan screens | pharmaceutical | Sarah Constantin | info@daphnia-labs.com | San Francisco | no | 2 | 2019 | 8/2/19 | |||||||||||||||||||
34 | Deciduous Therapeutics | yes | operating | activate endogenous immune cells to clear senescent cells | pre-clinical | therapy | senescence | senescence | ApoptoSENS | pharmaceutical | San Francisco | no | 1 | 2018 | QB3, Age1 | 7/11/19 | ||||||||||||||||||
35 | Denali Therapeutics | only brain | operating | drug discovery for neurodegeneration, optimized for brain delivery, guided by genetics & biomarkers | ph.1 trials | therapy | PD, ALS, AD, FTD, MS, neuroDs | 5 | small molecules, biologics | pharmaceutical | Ryan Watts, Carole Ho, Zach Sweeney | Scott Biller, David Holtzman, Eric Reiman, Kevan Shokat, Henrik Zetterberg, Huda Zoghbi, Marc Tessier-Lavigne | form | San Francisco | yes | DNLI | $1,534 | 230 | 237 | 2015 | DNL201, DNL151, DNL747 | 8/22/19 | ||||||||||||
36 | Dorian Therapeutics | yes | operating | block cellular senescence | pre-clinical | therapy | senescence | senescence | pharmaceutical | Maddalena Adorno, Benedetta di Robilant | form | San Francisco | no | 4 | 2018 | Longevity Fund, YC, Blumberg | MBC | 8/6/19 | ||||||||||||||||
37 | Elevian | yes | operating | regulate GDF11 & other circulating factors to restore regenerative capacity | pre-clinical | therapy | factors | cell-comm | CVD, T2D, AD, sarcopenia | pharmaceutical | Mark Allen, Tony Sandrassagra, Manisha Sinha, Orit Foord, Vongting Wang | Brock Reeve, Luis Alvarez, Scott Dylla, James Larrick | info@elevian.com | Boston | no | 12 | 2017 | raised seed | Kizoo, Thynk, Longevity Fund, Bold Capital | 5.5 | several | 8/22/19 | ||||||||||||
38 | Elysium Health | yes | operating | nutraceutical Basis to boost NAD+ w/ nicotinamide riboside (NR) & pterostilbene (related to resveratrol) | commercial, ph.1 trials | therapy | NAD+ | 7 | nutraceuticals | nutraceutical | Eric Marcotulli, Leonard Guarente, Mark Morris | 25+ inc. George Church, Ana Maria Cuervo, Vera Gorbunova, Jim Kirkland | care@elysiumhealth.com | New York | no | 54 | 2014 | raised B | SV Bank, General Catalyst | 31.2 | Basis | paper | 8/8/19 | |||||||||||
39 | Enclear Therapies | only brain | operating | devices to access & filter toxic proteins from CSF, 1st for ALS | pre-clinical | therapy | proteostasis | proteostasis | AmyloSENS | ALS, neuroDs | CSF access | device | Anthony DePasqua, Kasper Roet, William Gormley | Kevin Eggan, Clifford Woolf, Manuel Navia, Bernhardt Trout | form | Boston | no | 6 | 2018 | raised seed | Thiel Capital, Bioverge, Sanford Biosciences, Presight Capital | 2 | LabCentral | 8/14/19 | Various company summaries also mention monitoring of CSF. | |||||||||
40 | Epimorphy LLC | yes | operating | DTC Horvath methylation clock | commercial | diagnostic | biomarkers / methylome clock | epigenetic | n/a | blood test, urine test | unregulated test | Larry Jia | info@myDNAge.com | Los Angeles | no | 0 | 2017 | Zymo Research | myDNAge | 8/2/19 | ||||||||||||||
41 | Eterly | yes | operating | AI based anti-aging health & fitness monitoring and recs app w/ blockchain coins for incentives | app launched | recommendations | software | unregulated app | Andrew Ahachinsky | form | Vancouver, BC | no | 10 | 2016 | raised seed | Deep Knowledge Ventures | Longevity Token? | 8/22/19 | What is the relationship to Longevity Token (LTY) / Longevity United, whose website mentions Eterly as its front-facing app and some team members overlap based on LinkedIn, but CEOs are different, LTY's website doesn't seem to have updates since early 2018, and Eterly website doesn't mention Longevity Token. Are they distinct legal organizations? | |||||||||||||||
42 | Eternans | yes | operating | senolytics, peptide (see patent) | pre-clinical | senescence | senescence | ApoptoSENS | pharmaceutical | Yavuz A. | form | UK | no | 3 | 2017 | patent | 8/22/19 | |||||||||||||||||
43 | Everon Biosciences | yes | defunct? | small molecules & biologics platform based on proprietary aging biomarkers including a frailty index | pre-clinical | therapy | Alexander Polinsky, Andrei Gudkov, Olga Chernova | info@everonbio.com | Buffalo, NY | no | 6 | 2010 | several | 2 | 8/22/19 | News & publications end in 2017. | ||||||||||||||||||
44 | Fauna Bio | maybe | operating | comparative animal genomics & multi-omics for drug discovery to improve human health | pre-clinical | therapy | form | San Francisco | no | 5 | 2018 | raised seed | Longevity Fund, True Ventures (lead) | 4.1 | Age1 | 7/15/19 | Could go in an aging direction, but appears more committed to the idea of using insights from non-model non-human organisms for human health in general, not necessarily for aging. In favor of an aging categorization: Hibernation is a focus and has relevance for several age-related diseases. Aging is mentioned as a future area of research relevant to hibernation in 1 press article (but as distant future). Investment by Longevity Fund. Conclusion: Wait and see what indications, targets, pathways they go after initially. | |||||||||||||||||
45 | Fountain Therapeutics | yes | operating | unbiased screening platform for new aging targets using AI, vision, & cellular model of aging hallmarks | pre-clinical | therapy | info@fountaintx.com | San Francisco | no | 4 | 2018 | 5 | QB3 | 7/24/19 | ||||||||||||||||||||
46 | FoxBio / Antoxerene | yes | operating | drug platform using protein manufacturing tech, senolytics targeting p53 pathways (eg p53/FOXO4) | pre-clinical | therapy | senescence | senescence | ApoptoSENS | small molecules | pharmaceutical | Kelsey Moody, Adam Blanden, Cees Wortel | info@ichortherapeutics.com | Syracuse, NY | no | 5 | raised seed | Juvenescence, Kizoo | 11.5 | Ichor, Juvenescence | 8/9/19 | Ichor spun out Antoxerene. Antoxerene & Juvenescence created FoxBio as a 50-50 joint venture. Considering them (A & FB) as one here for now since FB has no website nor LIn employees. | ||||||||||||
47 | GEn1E Lifesciences | yes | operating | drug discovery platform for inflammatory & aging diseases; lead is p38α kinase inhibitor | pre-clinical | therapy | acute lung injury, agingD? | pharmaceutical | Ritu Lal, Clint Webb, Wendy Luo | David Young, Alan Levy, Robert Booth, Leonard Hayflick | Info (@) GEn1Elifesci.com | San Francisco | no | 3 | 2018 | 7/30/19 | Some profiles on 3rd party sites (older material?) omit mention of aging, instead saying a pipeline for rare diseases. No explanation p38 kinase inhibition's larger role in aging. Giving benefit of doubt for now for putting aging front and center and pledging age-related disease indications coming. | |||||||||||||||||
48 | Genome Protection | yes | operating | entolimod & other drugs for anti-aging & cancer, esp. by protecting genome, esp. against transposons | ph.2 trials | therapy | transposons | DNA | OncoSENS | various cancers | 3 | small molecules | pharmaceutical | Andrei Gudkov, Yakov Kogan, Katerina Andrianova | info@genomeprotection.com | Buffalo, NY | no | 3 | 2018 | seed | Norma Investments | 10.5 | Everon, Cleveland Biolabs | entolimod (drug) | several inc. peer-reviewed | 7/17/19 | also started with a portfolio of other anti-aging and anti-cancer drugs from parent Everon Biosciences | |||||||
49 | GenSight Biologics | yes | operating | allotopic expression w/ targeting to deliver mRNA to mitochondria, for retinal & neuro mito diseases | ph.3 trials | therapy | mitochondria | mitochondria | MitoSENS | NA eyeDs, AMD | 8 | viral gene therapy | pharmaceutical | Bernard Gilly, Barrett Katz, Harvey Masonson | Botond Roska, Jose-Alain Sahel, Jean Bennett, Ernst Bamberg, Connie Cepko, Serge Picaud, Luk Vandeberghe | Paris, NYC | yes | SIGHT.PA | $35 | 31 | 67 | 2012 | 7/6/19 | allotopic expression of mtDNA w/ targeting to deliver the mRNA to mitochondria could rescue mito aging; also in pre-clinical development for age-related dementias | ||||||||||
50 | Gero LLC | yes | operating | physics based data/AI biomarkers f/ blood metabo- & proteo-omes & activity data, as service & app | commercial | diagnostic | biomarker | life insurance | unregulated test | Peter Fedichev, Nikolai Kovtunenko, Kristina Zakurdaeva | Robert Shmookler, Aubrey de Grey, Dobri Kiprov | info@gero.ai | Moscow, Singapore | no | 46 | 2012 | several, inc. peer reviewed | 8/2/19 | ||||||||||||||||
51 | Gerostate Alpha | yes | operating | pharmaceutical scerening platform to treat aging | pre-clinical | therapy | lifespan screens | pharmaceutical | Simon Melov, Gordon Lithgow, Mark Lucanic | SMELOV@GEROSTATEALPHA.COM | San Francisco | no | 5 | 2018 | YC, CRCM | 0.15 | 9/12/19 | |||||||||||||||||
52 | Gordian Biotechnology | yes | operating | unbiased, high-throughput, in-vivo screening platform for aging w/ gene therapy & single-cell RNAseq | pre-clinical | therapy | gene therapy | pharmaceutical | Francisco LePort, Martin Borch Jensen, Daniel Fuentes, Chris Towne | Tom Rando, Randy Platt, David Schaffer, Laura Deming, Edward Lanphier, Thomas Ebeling | info@gordian.bio | San Francisco | no | 5 | 2018 | Longevity Fund, NJF | QB3, Age1 | 8/6/19 | ||||||||||||||||
53 | Guided Clarity | yes | operating | mitochondria-targeted therapies: trigger apoptosis in cancer, increase mitophagy for aging | pre-commercial | therapy | mitochondria | mitochondria | MitoSENS | cancer, ageDs, neuroDs | Helen Chen, Olof Mollstedt | form | San Francisco | no | 2 | 2018 | SOSV/IndieBio | 11/7/19 | ||||||||||||||||
54 | Hanako Biotech | yes | operating | screening platfom for oligonucleotide senolytics with high selectivity & senolytic activity | pre-clinical | therapy | senescence | senescence | ApoptoSENS | oligonucleotides | pharmaceutical | Yuri Shoshan, Noam Pilpel, Amir Bar-Shai, Yossi Ovadya, Dina Raichlin | Ido Bachelet | info@hanako.bio | Israel | no | 1 | 2019 | 11/13/19 | 11/13/19 | ||||||||||||||
55 | Human Rejuvenation Biotechnologies | yes | defunct? | clearance of 7-ketocholesterol (a type of lipofuscin) for atherosclerosis | pre-clinical | therapy | LysoSENS | atherosclerosis | pharmaceutical | contact@human.bio | Phoenix, AZ | no | 0 | 2014 | Jason Hope | 8/9/19 | Defunct? All the The handful of employeees on LinkedIn say their employment here ended. William Adams' (linked in this cell) says "closure of company". | |||||||||||||||||
56 | Humanity Inc | yes | starting? | aging-focused health/wellness platform using biomarkers & self-experimentation | pre-commercial | Michael Geer, Peter Ward | UK | no | 2 | 2019 | 8/8/19 | |||||||||||||||||||||||
57 | Ichor Ttherapeutics | yes | operating | biopharma that spins off subsidiaries inc. senolytics, enzymes for lipofuscin, a CRO, & oral mAb mimetics | pre-clinical | therapy | LysoSENS | AMD, other undisclosed | small molecules, biologics | pharmaceutical | Kelsey Moody, Aaron Wolfe, Cornelis Wortel | info@ichortherapeutics.com | Syracuse, NY | no | 37 | 2013 | raised seed | Kizoo | 4.5 | Antoxerene, FoxBio, LysoClear, Auctus Biologics | several | 8/24/19 | LysoClear itself doesn't qualify for this list due narrow 1-disease focus, but the platform approach it came from does & lives in Ichor. Auctus could eventually qualify itself w/ similarities to Longevity Biotech, but too little info currently available publicly on indications it will target. | |||||||||||
58 | InSilico Medicine / Generait | yes | operating | Insilico: AI for drug discovery, biomarkers, & aging. Generait (formerly Juvenescence AI): JV for aging. | biomarkers | Alex Zhavoronkov, Marine Bozdaganyan, Ivan Ozerov, Jimmy Yen-Chu Lin, Polina Mamoshina | Charles Cantor, Michael Levitt, Bud Mishra, Donald Small, Yuri Nikolsky, Kristen Fortney, Alexey Moskalev, Ulrich Muehlner | zhu@insilicomedicine.com | Hong Kong, Moscow | no | 53 | 2014 | raised B | Qiming, Wuxi AppTec, Deep Knowledge Ventures, Juvenescence, Bold Capital, Jim Mellon | 51.3 | Juvenescence | sevenal | 9/10/19 | Largely AI for drug discovery (like some other companies not focused on aging) but also consistently focused on aging, publishing on aging, launching aging-focused sites, creating aging-related partnerships, etc. Recent post on Medium suggests shifting focus away from aging. If that happens, Insilico will drop off this list though perhaps Generait might stay if a proper 1st-class company in the sense of others here by then. | |||||||||||||||
59 | Integrated Health Systems | yes | operating | gives patients access to gene & cell therapies for anti-aging esp. telomeres & myostatin, BioViva partner | commercial | therapy | telomeres | telomeres | AD, cancer, kidneyDs, aging itself | viral gene therapy | medical tourism | a team of doctors | info@integrated-health-systems.com | British Virgin Islands | no | 1 | BioViva | 8/14/19 | Ex-USA travel not mentioned explicitly but apply-for-study link leads to https://mailchi.mp/bioviva-science.com/alzheimers/ which mentions travel to Mexico. Not to be confused with the other Integrated Health System (same exact name) at https://ihs911.com/ which does IT for senior living and related care facilities. | |||||||||||||||
60 | Intervene Immune | yes | operating | reverse thymus involution & (immune) aging w/ HGH+DHEA+others; provide thru collaborating physicians | commercial, pre-clinical | therapy | immune | RepleniSENS | Greg Fahy, Bobby Brooke | info@interveneimmune.com | Los Angeles | no | 2 | 2011 | Aging Cell, 2019 | patent | 9/12/19 | TRIIM trial results published in 2019 showed Horvath clock reversal of 2.5yrs over 1yr of study. | ||||||||||||||||
61 | iuve bio | yes | operating | DTC biomarkers of systemic chronic inflammation based on Stanford 1000 immunomes project & AI | commercial | diagnostic | biomarkers | blood test | unregulated test | Wolfgang Daum, Zuzana Krejciova-Rajaniemi | Mark Davis, David Furman, Joseph Wu | info@iuvebio.com | San Francisco | no | 2 | 2018 | Age1 | iAge | 8/2/19 | |||||||||||||||
62 | Juvena Therapeutics | yes | operating | discovery platform for proteins promoting tissue regeneration, using proteomics, vision, ML | pre-clinical | therapy | factors, stem-cells | stem-cells, cell-comm | biologics | pharmaceutical | Hanadie Yousef, Jeremy O'Connell | Mike Nohaile, David Schaffer, Joe Wu, Peter Jackson, Irina Conboy | form | San Francisco | no | 10 | 2017 | raised seed | Felicis, Compound, Front Seat, Barney Pell | 4.3 | Youssef's patents | 9/13/19 | ||||||||||||
63 | Juvenescence | yes | operating | biopharma umbrella company that creates/invests-in other companies for aging therapeutics | see portfolio pipelines | therapy | Greg Bailey, Declan Doogan, Colin Watts, Alexander Pickett, Margaret Jackson, Nafees Malik | Annalisa Jenkins, Steve Felstead, Howard Federoff, Sef Kurstjens, Charlie Roberts, Jeff Sprouse | form | no | 10 | 2016 | raised B | Foresite, Grok, IPGL, Jim Mellon | 165 | several portfolio companies | 8/26/19 | |||||||||||||||||
64 | Life Biosciences | yes | operating | biopharma umbrella company that creates/invests-in other companies for aging therapeutics | see portfolio pipelines | therapy | Mehmood Khan, Tristan Edwards, John Amatruda, Jennifer Cermak, William Avery | Nir Barzilai, Lindsay Wu | info@lifebiosciences.com | Boston | no | 53 | 2017 | raised B | 75 | several portfolio companies | 8/26/19 | |||||||||||||||||
65 | Life Epigenetics | yes | operating | B2B epigenetic tests as a service (for pharma & nutraceutical clients, research, insurance) | commercial | diagnostic | biomarkers / methylome clock | life insurance | saliva sample | unregulated test | Jon Sabes, Brian Chen, Randy Olson | Michael Curran, Morgan Levine, Raymond McCuley, Andreas Muller | info@lifeegx.com | Minneapolis | no | 19 | 2016 | subsidiary of GWG Holdings (a public company) | GWG Holdings | 7/30/19 | Sister company YouSurance (also a subsidiary of GWG) in beta beginning to sell DTC life insurance (using Life Epigenetics service?) | |||||||||||||
66 | LipidEv (Lipid Evolution Ltd.) | yes | operating | anti-inflammatory lipids (specialized proresolving mediators) that decline w/ age | pre-clinical | therapy | various agingDs & inflammatoryDs | Derek Clissold | info@lipidev.co.uk | Reading, UK | no | 1 | 2014 | related papers | 8/2/19 | |||||||||||||||||||
67 | Longeveron | yes | operating | allogeneic mesenchymal stem cells f/ bone marrow | ph.2 trials | therapy | stem-cells | stem-cells | RepleniSENS | AF, AD, metabolicDs | 5 | cell therapy | pharmaceutical | Geoff Green, Joshua Hare, Anthony Oliva | Jeremy Walston, Laura Dugan, Elena Volpi, Hidenori Arai | form | Miami | no | 12 | 2014 | raised seed | 7 | 8/23/19 | |||||||||||
68 | Longevity Biotech | yes, but see notes | operating | platform peptides long-lived w/ oral administration, 1st or neurodegeneration (via VIP receptors) & T2D | clinical trials | therapy | PD, neuroDs, T2D, cancer | 1 | peptides | pharmaceutical | Scott Shandler, Samuel Gellman, Uma sinha | William Degrado, Howard Gendelman, Soumitra Ghosh, Chris Rhodes, James Waschek | Info@LongevityBiotech.com | Philadelphia | no | 6 | 2010 | NMSS, Thiel/Breakout, MJF | 0.8 | LBT-3627, LBT-6030 | several | 8/23/19 | Longevity in the name appears to refer to the stability of the peptides, not longevity of the patient. Nonetheless, the platform's early pipeline indications include a variety of age-related diseases, and mostly age-related diseases, even though aging/longevity doesn't seem to be a company mission or criterion, eg based on interview here: https://www.sciwri.club/archives/7375 | |||||||||||
69 | Longevity Bridge | yes | operating | biomarkers of aging esp. NAD biomarkers, 1st through patient-funded study (also see notes) | pre-commercial | diagnostic | NAD+ | blood tests | unregulated test | Maria Entraigues Abramson, Gary Abramson | Greg Fahy, Aubrey de Grey, Alexandra Stolzig, Michael Rae, Mike Kope | mail@longevitybridge.com | Los Angeles | no | 2 | 2017 | 7/30/19 | LinkedIn company page self description suggests plan for DTC products/services for healthspan/lifespan. | ||||||||||||||||
70 | LyGenesis | yes | operating | regrow organs in one's own lymph nodes, 1st for liver diseases, later thymus, pancreas, & kidneys | pre-clinical | therapy | RepleniSENS | liverDs | pharmaceutical? | Eric Lagasse, Paulo Fontes, Michael Hufford | form | Pittsburgh | no | 3 | 2017 | raised A | Juvenescence | 3 | Juvenescence | a couple papers | 8/23/19 | |||||||||||||
71 | Mesoblast | yes | operating | allogeneic mesenchymal stem cells for inflammatory conditions | ph.3 trials, approval in Japan & Europe | therapy | stem-cells | stem-cells | RepleniSENS | GVHD, HF, chronic back pain, OA, diabetic nephropathy | 34 | cell therapy | pharmaceutical | Silviu Itescu, Fred Grossman, Roger Brown | info@mesoblast.com | Melbourne | yes | MESO | $3,284 | 81 | 91 | 2004 | Revascor, Remestemcel-L, MPC-06-ID | many | some info | 8/23/19 | A lot of focus on non-age-related conditions, but stem-cell tech clearly applicable to aging too with several aging-related indications. Claimed first allogeneic stem-cell therapy approved in Japan & first in Europe. | |||||||
72 | Methuselah Health | yes | operating | protein post-translational modification analysis for drug discovery for proteostasis | pre-clinical | therapy | proteostasis | proteostasis | AmyloSENS | drugs | pharmaceutical | David Grainger, David Mosedale, Mary Donnelly | info@methuselah-health.com | Cambridge, UK | no | 2 | 2015 | Medicxi, Index Ventures | 11/14/19 | 11/14/19 | ||||||||||||||
73 | Minovia Therapeutics | yes | operating | autologous stem cells enriched w/ mitochondria to transfer to other cells, for mitochondria dysfunction | ph.2 trials | therapy | mitochondria / mito-transfusion, stem-cells | mitochondria | MitoSENS | NA mitoDs, AD, PD, AMD | 2 | cell therapy | pharmaceutical | Natalie Yivgi-Ohana, Noa Sher, Eyal Shoshani, Hadass Reich | Israel | no | 5 | 2011 | https://patents.justia.com/assignee/minovia-therapeutics-ltd | 7/6/19 | more details at http://minovia.com/mitochondrial-augmentation-therapy/ & http://minovia.com/open-questions/ | |||||||||||||
74 | Mitochondrial Transfusion Inc. | yes | operating | extract stem cells, expand & extract youthful mitochondria, transfuse back to body | pre-clinical | therapy | mitochondria / mito-transfusion | mitochondria | MitoSENS | AD, PD, CVD, sarcopenia, other agingDs | cell/organelle therapy | pharmaceutical | Tom B. | San Francisco | no | 1 | 2018 | 7/10/19 | ||||||||||||||||
75 | Mitoconix Bio | only brain | operating | drugs for mitochondria health for dementias, 1st by inhibiting pathological mito fission | pre-clinical | therapy | mitochondria | mitochondria | MitoSENS | HD, PD, AD | peptides | pharmaceutical | Gili Hart, Lior Weissman | Daria Mochly-Rosen, Orian Shirihai | Israel | no | 10 | 2016 | raised A ('17) | FutuRx, Remiges, OrbiMed, Dementia Discovery Fund, Arix Bioscience, RMGP | 20 | 7/7/19 | lead peptide inhibits Drp1 | |||||||||||
76 | Mitokinin | only brain | operating | develop neo-substrates that modify kinase activity for mitochondria & neuro diseases, 1st for PD | pre-clinical | therapy | mitochondria | mitochondria | MitoSENS | PD, HD, other mito & neuroDs? | pharmaceutical | Kevan Shokat, Nicholas Hertz, Daniel de Louret | M. Flint Beal, X. William Yang, Ray Truant | San Francisco | no | 10 | 2017 | 5 | QB3 | https://patents.justia.com/assignee/mitokinin-llc | 7/10/19 | |||||||||||||
77 | Mount Tam Biotechnologies | yes | operating | drug platform for mTOR modulating rapalogs with selective inhibition of mTORC1 | pre-clinical | therapy | metabolic / mTOR | nutri-sense | Lupus, MS, cancer, PD, HD | small molecules | pharmaceutical | Richard Marshak, James Stapleton | Bryan Cox, Jim Stolzenbach | jim@mounttambiotech.com | Burlington, VT | yes | MNTM | #N/A | 2 | 2 | 2014 | TAM-01 | 8/24/19 | |||||||||||
78 | MyndYou | only brain | operating | cognition eval app w/ AI to passively track movement & conversation, platform for therapists | commercial | diagnostic | biomarker | AD, other MCI | mobile app, telecommunications? | Ruth Poliakine Baruchi, Itay Baruchi, | form | Israel | no | 11 | 2016 | raised seed | Amplifyher, Female Founders Fund, Howard Morgan | Mizuho | 7/22/19 | Company webpage indicates more palliative focus than other cognitive testing app companien (eg NeuroTrack, Altoida), but clearly the technology has the potential to be used as cognitive decline biomarker/diagnostic. Being deployed currently as more of a augmentative tool for therapists? | ||||||||||||||
79 | Napa Therapeutics | yes | operating | drug discovery pursuing novel targets related to NAD metabolism using drug discovery AI + NAD science | pre-clinical | therapy | NAD+ | small molecules | pharmaceutical | Eric Verdin (presumably not employee?) | no | 1 | 2019 | Juvenescence | 3 | Juvenescence, Insilico Medicine | 7/31/19 | |||||||||||||||||
80 | Navitor Pharmaceuticals | yes | operating | drug discovery targeting mTORC1 modulation | ph.1 trials | therapy | metabolic / mTOR | nutri-sense | depression, HD, MCI, muscle wasting | 1 | small molecules | pharmaceutical | George Vlasuk, Eddine Saiah, James ("Randy") Owen | David Sabatini, Michael Hall, Brian Hubbard, Brendan Manning, Mark Murcko | 3 emails | Boston | no | 24 | 2010 | raised C | Brace Pharma, J&J, Sanofi, SR One, Polaris, Longevity Fund | 78 | NV-5138 | several peer reviewed | 7/31/19 | |||||||||
81 | NemaLife Inc. | yes | operating | automating C.elegans HTS inc. healthpan/lifespan w/ microfluidics, computer vision, & data intelligence | commercial? | tool | lifespan screens | some specific worm disease models | tool as product, service | unregulated tool | Siva Vanapalli, Mizanur Rahman | info@nemalifeinc.com | Lubbock, TX | no | 4 | 2018 | bioRxiv preprint | 7/17/19 | the microfluidics approach distinguishes this from some other worm automation work, eg allowing automated removal of offspring to allow focus on the aging adult worms | |||||||||||||||
82 | NeuroTrack | only brain | operating | eye-tracking cognitive (esp. memory) 5min test & multimodal lifestyle digital intervention program | commercial? | diagnostic, therapy | biomarker | MCI | 3 | mobile app | regulated? diagnostic | Elli Kaplan, Nick Bott, Jordan Glenn | John Harrison, Richard Isaacson, Dorene Rentz, Mike Poole | support@neurotrack.com | San Francisco | no | 43 | 2012 | raised C | Founders Fund, Khosla, Marc Benioff, Social Capital, Sozo Ventures | 50.4 | Imprint Memory Assessment | https://aging.jmir.org/2018/2/e12031/ | 7/22/19 | ||||||||||
83 | Nuchido | yes | operating | nutraceutical for NAD+ w/o NR, includes regulators of pathways that make/lower NAD+ | pre-commercial | therapy | NAD+ | nutraceuticals | nutraceutical | Nichola Conlon | Tom Kirkwood | Newcastle, UK | no | 5 | 2017 | Deepbridge | Time Capsule | poster | 8/9/19 | List of ingredients does not seem to be available yet. | ||||||||||||||
84 | Oisin Bio (& OncoSenX) | yes | operating | targeted non-viral gene therapy based on DNA expression, for senescent cells & cancer (via spinout) | pre-clinical | therapy | senescence | senescence, DNA | ApoptoSENS, OncoSENS | cancer (all solids), more TBD | non-viral gene therapy | pharmaceutical | Matt Scholz, Gary Hudson, John Lewis | form | Seattle | no | 12 | 2014 | closed seed | Methuselah, Kizoo | 3 | Entos Pharmaceuticals | 7/31/19 | Spun out OncoSenX for cancer (not on this list since devoted only to cancer, but for the purposes of this list the 2 companies are best considered as one). | ||||||||||
85 | OneSkin Technologies | yes | operating | screening platform using 3D human skin culture & skin age clock, 1st therapy a topical senolytic peptide | pre-clinical | therapy | senescence | senescence | ApoptoSENS | peptide for topical use | regulated cosmetic | Carolina Oliveira, Andres Ochoa, Alessandra Zonari, Mariana Boroni | information@oneskintech.com | San Francisco | no | 10 | 2016 | raised seed | SOSV/IndieBio | 2.2 | QB3 | OS-1, OS-2 | 8/2/19 | |||||||||||
86 | OpenCures / OpenOme | yes | operating | DTC multi-omics tests & education | commercial (limited early access) | diagnostic | biomarker | blood test, functional test | unregulated test | Kevin Perrott, Mark Hamalainen | contact@opencures.org | San Francisco | no | 1 | 2018 | 8/24/19 | ||||||||||||||||||
87 | Osiris Green | yes | defunct? | DTC aging biomarkers esp. methylation clock, but not accepting new orders | commercial | diagnostic | biomarkers / methylome clock | epigenetic | blood test | unregulated test | Neil Copes | form | Tampa, FL? | no | 1 | 2016 | 7/19/19 | |||||||||||||||||
88 | Oxitope Inc. | yes | starting? | mAbs for oxidative damage & chronic inflammation by targeting oxidized lipids, for aging diseases | pre-clinical | therapy, diagnostic | targeted elimination | CVD, cancer, obesity, metabolicDs, OA, neuroDs, liverDs | biologics | pharmaceutical | Alexander Martinez? | form | San Diego | no | 1 | 2018 | a few peer reviewed | 7/19/19 | ||||||||||||||||
89 | Pano Therapeutics | yes | starting? | mitochondria drugs for aging & metabolic disorders | pre-clinical | therapy | mitochondria | mitochondria | MitoSENS | small molecules | pharmaceutical | Francesca Fieni | San Francisco | no | 1 | 2017 | 8/27/19 | Not to be confused with 2 similarly named bio/pharma companies: Oxford, UK based Panos Therapeutics nor with Pano.com, an SF area biotech/pharma incubator. | ||||||||||||||||
90 | Pentraxin Therapeutics | yes | IP holding company | small molecule targeting amyloid component for AD & separate CRP inhibition program | ph.2 trials (Europe) | therapy | proteostasis, targeted elimination | proteostasis | AmyloSENS | AD, CVD, neuroDs | 1 (but old GSK trials of CPHPC also relevant for safety) | small molecules | pharmaceutical | Mark Pepys | contact@pentraxin.com | London | no | 1 | 2001 | miridesap (formerly CPHPC) | several peer reviewed | 7/19/19 | ||||||||||||
91 | PharmatrophiX | only brain | operating | small moleculels for neurodegenerative diseases targeting neurotrophin repceptors, esp. p75 | ph.2 trials | therapy | AD, neuroDs | 1 | small molecules | pharmaceutical | Anne Longo, Frank Longo | anne@pharmatrophix.com | San Francisco | no | 2 | 2005 | Dolby | 11.8 | LM11A-31 | several inc. peer reviewed | https://patents.justia.com/assignee/pharmatrophix-inc | 7/24/19 | ||||||||||||
92 | Ponce de Leon Health / Rejuvant | yes | operating | nutriceutical shown to increase lifespan in c.elegans & mammals, key ingredient is alpha-ketoglutarate | commercial | therapy | nutraceuticals | nutraceutical | Tom Weldon | Rejuvant@webcsr.info | no | 5 | 2015 | raised seed | Partisan Mngmnt | Rejvant | 8/9/19 | Claimed scienc-backed mechanisms of action include blocking SASP and reverting methylation state to be more youthful. | ||||||||||||||||
93 | Proclara Biosciences | yes | operating | treat multiple misfolded proteins (Aβ, Tau, α-synuclein, AL, TTR) by targeting the shared amyloid fold | ph.1 trials | therapy | proteostasis, targeted elimination | proteostasis | AmyloSENS | AD, PD, amyloidosis | 4 | biologics | pharmaceutical | Richard Fisher, David Michelson, Rajaraman Krishnan | Paul Aisen, David Hafler, David Holtzman, Bradley Hyman, Kenneth Marek, Greg Petsko, Beka Solomon | form | Boston | no | 27 | 2007 | raised E | Merieux, Shire, Smedvig | 110 | NPT088, NPT189 | couple papers & posters | 7/19/19 | Formerly named NeuroPhage Pharmaceuticals. | |||||||
94 | Prodrome Sciences | yes | operating | metabolomics for early disease detection & therapy for brain diseases by boosting plasmalogen (a lipid) | pre-clinical, commercial (in Canada) | diagnostic, therapy | biomarker, mitochondria? | mitochondria? | MitoSENS? | PD, neuroDs, cancers, CVD, T2D, liverDs | 0 but 1 soon | nutraceutical? | regulated diagnostic, nutraceutical? | Dayan Goodenowe, Vijitha Senanayake | Ian Wright, John Ryan, Kevin Perrott | info@prodromesciences.com | Saskatoon, Canada; San Diego | no | 7 | 2016 | Prodrome Health | ProdromeScan | several peer reviewed: see both Detect & Cure pages, plus https://www.ncbi.nlm.nih.gov/pubmed/31022959 | 7/20/19 | Diagnostic launched commercially for contract research (https://www.prodromesciences.com/component/content/article/79-blog/98-contract-research-services-launch?Itemid=437) but linked page no longer live. Health clinic operating commercially in Canada (http://prodromehealth.com/). | |||||||||
95 | Proteostasis Therapeutics | yes | operating | modulate protein homeostasis | ph.2 trials | therapy | proteostasis | proteostasis | AmyloSENS | cycstic fibrosis, PD, AD | 7 | small molecules? | pharmaceutical | Meenu Chhabra, Ben Munoz, Geoffrey Gilmartin | F. Ulrich Hartl, Daniel Finley, Jeffrey Kelly, Randall King, Gregely Lukacs, Richard Morimoto | form | Boston | yes | PTI | $56 | 48 | 62 | 2006 | PTI-428, PTI-801, PTI-808 | presentations & papers | 8/24/19 | ||||||||
96 | Rejuvenate Bio | yes | operating | gene therapy for dogs (eventually humans), 1st for mitral valve disease | pre-veterinary-study | therapy | heart & kidney failure, obesity, T2D | gene therapy | veterinary | Daniel Oliver, George Church, Noah Davidsohn, Jihyun Kim, Jordan Willis | San Diego | no | 4 | 2018 | seed | Digitalis | 7/19/19 | |||||||||||||||||
97 | Rejuvenation Technologies | yes | operating | extend telomeres via nucleoside-modfied TERT mRNA | pre-clinical | therapy | telomeres | telomeres | RNA | pharmaceutical | John Ramunas, Glenn Markov, Helen Blau | info@rejuvenationtech.com | San Francisco | no | 1 | 2017 | paper | 8/13/19 | ||||||||||||||||
98 | Repair Biotechnologies | yes | operating | reverse atherosclerosis by improving macrophages & rejuvenate the thymus w/ FOXN1 | pre-clinical | therapy | immune, gene-therapy | LysoSENS, RepleniSENS | atherosclerosis, hypercholesterolemia, cancer risk, HIV non-responders | gene therapy | pharmaceutical | Reason, Bill Cherman, Marc Ridilla, Jay Mukherjee | Richard Honkanen, Graham Pawelec, David Thomas, Aubrey de Grey | info@repairbiotechnologies.com | Syracuse, NY | no | 3 | 2018 | raised seed | Jim Mellon, Thynk, Emerging Longevity, SENS | 2.2 | 8/1/19 | ||||||||||||
99 | resTORbio | yes | operating | selective mTORC1 inhibitor | ph.3 trials | therapy, preventative | metabolic / mTOR, immune | nutri-sense | respiratory illness, PD, heart failure, other agingDs | 1 | small molecule | pharmaceutical | Chen Schor, Joan Mannick, Sarb Shergill | contact@restorbio.com | Boston | yes | TORC | $40 | 21 | 28 | 2016 | Novartis | RTB101 | 8/4/19 | ||||||||||
100 | Retrotope | yes | operating | deuterium lipids to prevent oxidation, for mitochondria health, for mito & neurodegenerative diseases | ph.2-3 trials | therapy | mitochondria | mitochondria | MitoSENS | NA mitoDs (FA, INAD), dementias | 3 | lipid small molecules | pharmaceutical | Robert Molinari, Mikhail Shchepinov, Peter Milner | Tom Brenna, Anatoly Buchachenko, Charles Cantor, Amato Giaccia, Aubrey de Grey, Richard Haas, Michael Murphy, David Shima, Jan Vijg | San Francisco | no | 17 | 2006 | Timur Artemev | 22 | list in white paper | 7/7/19 |
Loading...